<DOC>
	<DOCNO>NCT00819052</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy nevirapine extend release ( NVP XR ) base regimen HIV-1 infect patient receive nevirapine immediate release ( NVP IR ) base regimen least 18 prior week therapy .</brief_summary>
	<brief_title>Switching Nevirapine Immediate Release ( IR ) Based Regimen Nevirapine Extended Release ( XR ) Based Regimen Human Immunodeficiency Virus One ( HIV-1 ) Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion criterion : HIV infect subject treat Viramune base regimen . A subject meet follow inclusion criterion eligible participation study : 1 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . 2 . HIV1 infect male female least 18 year . 3 . Treatment Viramune regimen least precede 18 week . 4 . Background therapy lamivudine/ abacavir ( 3TC/ABC ) ( Kivexa® EU ; Epzicom US ) , emtricitabine/tenofovir ( FTC/TDF ) ( Truvada ) lamivudine/zidovudine 3TC/AZT ( Combivir® ) . 5 . An HIV viral load &lt; 50 copies/mL precede 3 month . 6 . An HIV viral load &lt; 50 copies/mL screening ( Visit 1 ) . 7 . Acceptable screen laboratory value indicate adequate baseline organ function follow exception : alanine aminotrnasferase ( ALT ) asparatate aminotransferase ( AST ) &lt; 2.5 × upper limit normal ( ULN ) Division Acquired Immunodeficiency Syndrome ( DAIDS Grade 1 ) . 8 . Willingness abstain ingest medication list contraindicated Summary Product Characteristics ( SPC ) package insert ( PI ) Investigator 's Brochure study . 9 . Karnofsky performance score &lt; 70 Exclusion criterion : Subjects meet one follow criterion exclude study : 1 . Current treatment HIV protease inhibitor 2 . Participation another trial use investigational medicine within two month prior Day 1 study 3 . Female patient childbearing potential : 1 . Have positive serum pregnancy test screening . 2 . Are breast feed . 3 . Are plan become pregnant 4 . Are willing use doublebarrier method ( simultaneous use two different method diaphragm spermicidal substance condom ) contraception , require ethinyl estradiol administration . Barrier method contraception include diaphragm spermicidal substance , condom female , cervical cap condoms.. 4 . Laboratory parameter &gt; DAIDS grade 2 Coagulation prothrombin time ( PT ) , partial thromboplastin time ( PTT ) , International Normalized ratio ( INR ) Hematology ( absolute platelet , white blood cell ( WBC ) , absolute neutrophil count , hemoglobin ) Biochemistry ( total bilirubin , amylase , serum creatinine , fast glucose , lactate , alkaline phosphatase ) 5 . Laboratory parameter &gt; DAIDS grade 3 Total triglyceride ( total cholesterol restriction ) 6 . Hypersensitivity ingredient test product 7 . Active drug abuse chronic alcoholism . 8 . Hepatic cirrhosis stage ChildPugh B C 9 . History severe acute illness within 60 day prior Day 1 , malignancy condition would make patient , opinion investigator , unsuitable trial 10 . Inability comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>